Home » Stocks » Avita Therapeutics

Avita Therapeutics, Inc. (RCEL)

Stock Price: $23.50 USD -0.37 (-1.55%)
Updated Oct 21, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 2.52B
Revenue (ttm) 18.19M
Net Income (ttm) -42.03M
Shares Out 107.34M
EPS (ttm) -10.35
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 21, 2020
Last Price $23.50
Previous Close $23.87
Change ($) -0.37
Change (%) -1.55%
Day's Open 23.64
Day's Range 23.41 - 23.84
Day's Volume 43,176
52-Week Range 20.73 - 34.90

More Stats

Market Cap 2.52B
Enterprise Value 2.45B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 107.34M
Float 105.06M
EPS (basic) n/a
EPS (diluted) -10.35
FCF / Share -5.75
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 252,539
Short Ratio 1.98
Short % of Float 0.24%
Beta 0.84
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 138.68
PB Ratio 7.62
Revenue 18.19M
Operating Income -42.68M
Net Income -42.03M
Free Cash Flow -23.34M
Net Cash 71.92M
Net Cash / Share 0.67
Gross Margin 83.65%
Operating Margin -234.64%
Profit Margin -231.10%
FCF Margin -128.30%
ROA -49.29%
ROE -90.16%
ROIC -2,649.40%
Key stats in USD, based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (8)

Buy 7
Overweight 1
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$30.85*
(31.28% upside)
Low
5.88
Current: $23.50
High
60.00
Target: 30.85
*Average 12-month USD price target from 7 stock analysts.

Financial Performance

Financial numbers in millions AUD.

Financial Overview

Year20202019201820172016
Revenue18.1911.408.665.131.81
Revenue Growth59.62%31.54%68.74%184.18%-
Gross Profit15.2210.128.125.462.09
Operating Income-42.68-25.53-13.84-8.89-8.12
Net Income-42.03-25.10-12.74-8.17-5.52
Shares Outstanding20.2916.069.33--
Earnings Per Share-10.35-7.80-6.85--
Operating Cash Flow-22.75-19.25-12.96-6.08-5.64
Capital Expenditures-0.59-1.02-0.37-0.31-0.03
Free Cash Flow-23.34-20.27-13.33-6.38-5.67
Cash & Equivalents73.8420.37---
Total Debt1.92-0.10--
Net Cash / Debt71.9220.37-0.10--
Assets82.4625.7816.345.44-
Liabilities10.064.952.851.81-
Book Value72.4020.8313.493.64-
Numbers in millions AUD, except per-share numbers.

Company Profile

Company Details

Full Name Avita Therapeutics, Inc.
Country United States
Employees 98
CEO Michael S. Perry

Stock Information

Ticker Symbol RCEL
Stock Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Unique Identifier NASDAQ: RCEL

Description

Avita Medical Limited operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients eighteen years and older. The company has a research collaboration with the University of Colorado School of Medicine to establish and explore development of a spray-on treatment for patients with epidermolysis bullosa. The company is based in Valencia, California.